Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine, speaks about common misconceptions within the treatment of narcolepsy-related excessive daytime sleepiness, and how combination therapy may play a role.
A misconception within the treatment of narcolepsy-related excessive daytime sleepiness is that it can be controlled by one therapy, but combination therapy is likely needed to address the full scope of disease burden, said Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine.
Transcript
What is a common misconception within the treatment of narcolepsy-related excessive daytime sleepiness?
I think that most physicians think that the excessive sleepiness in narcolepsy can be controlled entirely with 1 medication. I think what we're finding is that the majority of patients need multiple medications—2, or in some cases, even 3 medications.
So, the important thing about treating sleepiness is to get patients as much control as possible, so the patient's quality of life, occupation, and education are not adversely affected by the narcolepsy. I think one of the misconceptions that physicians have is that they might just prescribe one medication and reach a sort of maximum dosage, and think that that's the end of treatment. But I think we need to go a little bit further to try to produce treatments that really make major differences to patients and this often requires a combination therapy.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
2 Commerce Drive
Cranbury, NJ 08512